Empacoza trio xr 10-5-1000 mg 30tab 6224002652027

Empacoza trio xr 10-5-1000 mg 30tab 6224002652027

Description:

Empacoza Trio XR 10/5/1000 mg is a prescription oral antidiabetic medicine in extended-release film-coated tablets, combining three active ingredients: empagliflozin, linagliptin, and metformin. It is designed for adults with type 2 diabetes mellitus to help improve blood glucose control when diet and exercise alone are not sufficient, and when combination therapy with these agents is appropriate. This triple therapy targets different mechanisms of glucose regulation in the body, supporting better glycemic control and helping reduce the risk of diabetes-related complications when used as part of a comprehensive diabetes management plan.

Indications:

• Management of type 2 diabetes mellitus in adults as an adjunct to diet and exercise.
• For patients who are inadequately controlled on metformin alone or metformin in combination with empagliflozin and/or linagliptin.
• For patients already receiving empagliflozin, linagliptin, and metformin as separate tablets who wish to switch to a single combination tablet for convenience and improved adherence.
• Helps reduce elevated fasting and postprandial (after-meal) blood glucose levels.
• May contribute to reduction of diabetes-related long-term complications when used as part of a comprehensive treatment plan including diet, exercise, and regular monitoring.

Active Ingredients / Key Components:

• Empagliflozin – 10 mg per tablet (sodium-glucose co-transporter 2 (SGLT2) inhibitor).
• Linagliptin – 5 mg per tablet (dipeptidyl peptidase-4 (DPP-4) inhibitor).
• Metformin hydrochloride (extended release) – 1000 mg per tablet (biguanide class).
• Other excipients: The full list of inactive ingredients (excipients, coating agents, stabilizers, colorants) is not available in the provided information. Please refer to the official package insert for a complete ingredient list.

Dosage & Administration / How to Use:

• Use only as prescribed by a physician experienced in the management of type 2 diabetes.
• Typical dosing: 1 tablet once daily, with the dose strength selected by the physician based on current or previous therapy with empagliflozin, linagliptin, and metformin. The 10/5/1000 mg strength corresponds to empagliflozin 10 mg, linagliptin 5 mg, and metformin xr 1000 mg per tablet.
• Administration: Swallow the tablet whole with water. Do not crush, split, or chew, as this is an extended-release (xr) formulation.
• Take with food, preferably with the evening meal, to reduce gastrointestinal side effects related to metformin and to support steady glucose control.
• If a dose is missed, take it as soon as you remember on the same day. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not take a double dose.
• Regular monitoring of blood glucose, renal function, and, when appropriate, liver function and vitamin b12 levels is recommended during treatment.
• Dosage adjustments or discontinuation may be required in cases of reduced kidney function, dehydration, acute illness, or before certain medical imaging procedures or surgeries, as directed by your doctor.

Clinical Benefits:

• Triple mechanism of action: Combines SGLT2 inhibition, DPP-4 inhibition, and metformin’s insulin-sensitizing effect to improve overall glycemic control in type 2 diabetes.
• Helps lower fasting and postprandial blood glucose levels, contributing to improved HbA1c (glycated hemoglobin) over time.
• Empagliflozin promotes urinary glucose excretion by reducing renal glucose reabsorption, which may also support modest weight reduction and lower blood pressure in some patients.
• Linagliptin enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner, which reduces the risk of hypoglycemia compared with some other agents when used appropriately.
• Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity, forming the backbone of many type 2 diabetes regimens.
• Once-daily extended-release tablet improves convenience and may enhance treatment adherence compared with taking multiple separate tablets.

Warnings & Contraindications:

• Contraindicated in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
• Contraindicated in patients with severe renal impairment, end-stage renal disease, or on dialysis. Metformin-containing products carry a risk of lactic acidosis, especially in patients with significant renal dysfunction.
• Contraindicated in patients with known hypersensitivity to empagliflozin, linagliptin, metformin, or any of the excipients.
• Use with caution in patients with moderate renal impairment, elderly patients, or those at risk of volume depletion (e.g., due to diuretics, low blood pressure, or dehydration), as SGLT2 inhibitors can increase the risk of hypotension and acute kidney injury.
• Metformin should be temporarily discontinued in situations associated with hypoxia or increased risk of lactic acidosis (e.g., severe infection, shock, acute heart failure, dehydration, or before iodinated contrast imaging procedures) as advised by your doctor.
• Use with caution in patients with a history of pancreatitis, as DPP-4 inhibitors have been associated rarely with pancreatitis; advise patients to report persistent severe abdominal pain.
• Empagliflozin may increase the risk of genital mycotic (fungal) infections and urinary tract infections; maintain good genital hygiene and report symptoms early.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Most oral antidiabetic agents are not recommended during pregnancy; insulin is usually preferred.
• Consult your doctor before use if you have liver disease, heart failure, recurrent urinary tract infections, low blood pressure, or are taking diuretics or other glucose-lowering medications.
• Not intended to diagnose, treat, cure, or prevent any disease without medical supervision; this is a prescription-only medicine and must be used under healthcare professional guidance.
• Keep out of reach of children.

Side Effects:

• Common side effects may include gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal discomfort), especially at the start of metformin therapy; these often improve with continued use and taking the tablet with food.
• Empagliflozin-related effects may include increased urination, thirst, genital yeast infections (vulvovaginal candidiasis, balanitis), and urinary tract infections.
• Linagliptin may rarely cause nasopharyngitis, cough, or hypersensitivity reactions such as rash or angioedema.
• Hypoglycemia is more likely when this combination is used with insulin or insulin secretagogues (e.g., sulfonylureas); dose adjustment of the concomitant agent may be required.
• Serious but rare side effects include lactic acidosis (metformin), pancreatitis (linagliptin), severe urinary tract infections, ketoacidosis, or severe allergic reactions. Symptoms such as rapid breathing, muscle pain, severe abdominal pain, persistent nausea/vomiting, confusion, or swelling of the face/tongue require immediate medical attention.
• If you experience any unusual or severe symptoms, stop taking the medicine and contact your doctor or seek emergency medical care.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Product type: Oral antidiabetic medicine (prescription).
• Strength per tablet: empagliflozin 10 mg + linagliptin 5 mg + metformin hydrochloride xr 1000 mg.
• Form: Extended-release film-coated tablets.
• Pack size: 30 tablets per pack.
• Intended use: Adults with type 2 diabetes mellitus under medical supervision.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.